An Interesting Case of Serratia Endocarditis in a Patient With Chronic Myeloid Leukemia

Annapoorna Singh 1, Kathyayini Tappeta 2, Nikitha Chellapuram 3, Daulath Singh 4

1. Internal Medicine, University of Missouri–Kansas City School of Medicine, Kansas City, USA 2. Internal Medicine, St. George’s University School of Medicine, True Blue, GRD 3. Internal Medicine, Mayo Clinic, Rochester, USA 4. Internal Medicine/Hematology-Oncology, Stormont Vail Health, Topeka, USA

Corresponding author: Daulath Singh, daulath.aakash@gmail.com

Abstract

Serratia is a rare cause of infective endocarditis (IE) and usually occurs in patients with underlying risk factors, such as intravenous (IV) drug use, and human immunodeficiency virus patients. Gram-negative bacteria endocarditis is associated with high mortality when it involves the left side of the heart and often requires surgical intervention in addition to medical treatment. Although most gram-negative endocarditis cases are hospital-acquired, community cases have also been reported. Here, we present a case of Serratia endocarditis in an individual who was later diagnosed with chronic myeloid leukemia (CML) during the same hospitalization. The patient was treated with IV meropenem and started on targeted therapy for CML. CML is presumed to have likely predisposed the patient to bacteremia and IE.

Keywords: infective endocarditis, immunocompromised patient, chronic myeloid leukemia (cml), serratia endocarditis, aortic endocarditis

Introduction

Serratia species are gram-negative bacilli of the Enterobacteriaceae group. The genus Serratia consists of at least 20 species and S. marcescens is the main human pathogen [1]. S. marcescens has been associated with urinary tract infections, pneumonia, and bloodstream infections [1]. Although endocarditis caused by Serratia species is rare, it has been previously reported in intravenous drug users (IVDUs), human immunodeficiency virus (HIV) patients, and patients with prosthetics heart valves; however, it has never been reported in patients with chronic myeloid leukemia (CML). Here, we report a case of Serratia native valve endocarditis in a patient who presented with multiple symptoms and was newly diagnosed with CML during the same hospitalization.

This case report was previously presented as a poster at the Midwest Clinical & Translational Research Meeting held on April 4-5, 2019 in Chicago, Illinois, USA.

Case Presentation

A 40-year-old Caucasian male with a history of bicuspid aortic valve (BAV) presented to our hospital with left upper quadrant abdominal pain, nausea, vomiting, diarrhea, urinary frequency, and lethargy for two days. The patient also had sudden onset of dizziness, rigors, and low back pain one day before the presentation. He visited an urgent care center where he was negative for influenza and was subsequently sent home. On presentation, body temperature was 103.1°F; laboratory values are listed in Table 1. Computed tomography (CT) of the abdomen and pelvis showed mild hepatomegaly, mild splenomegaly, and possible splenic infarcts (Figure 1A). CT of the head without contrast was performed due to acute encephalopathy which showed no acute intracranial process (Figure 1B). A transthoracic echocardiogram (TTE) showed a normal ejection fraction of 55%, no valvular vegetation. BAV with mild stenosis (mean gradient of 21 mmHg), and elevated central venous pressure (Figure 1C). Platelet counts were normal on presentation (Table 1) but dropped to 40,000/µL on the third day of hospitalization. Duplex ultrasound of lower extremities was negative for thrombosis. The hematology team performed a bone marrow biopsy due to leukocytosis to rule out the malignant process.
| Labs                        | Lab values | Reference values |
|-----------------------------|------------|------------------|
| White blood cell count      | 79,000/µL  | 4.00–11.00/µL    |
| Platelet count              | 170,000/µL | 140,000–400,000/µL |
| Aspartate transaminase      | 78 IU/L    | 15–46 IU/L       |
| Alanine transaminase        | 58 IU/L    | 0–49 IU/L        |
| Total bilirubin             | 3.2 mg/dL  | 0.2–1.3 mg/dL    |
| Serum creatinine            | 2.4 mg/dL  | 0.6–1.3 mg/dL    |
| Urinalysis                  |            |                  |
| White blood cell count      | 11–20/HPF  | 0–3/HPF          |
| Red blood cell count        | 6–10/HPF   | 0–3/HPF          |
| Leukocyte esterase          | Negative   | Absent           |
| Nitrites                    | Negative   | Absent           |
| Bacteria                    | Large      | Absent           |
| Lactate dehydrogenase       | 1,801 IU/L | 313–618 IU/L     |
| International normalized ratio | 2.2       | 1                |
| Partial thromboplastin time | 24.5       | 11.4–15.0 seconds |
| Cerebrospinal fluid analysis|            |                  |
| White blood cell count      | 1,747/µL   | 0–5/µL          |
| Neutrophils                 | 91%        | 0–6%            |
| Red blood cell count        | <3,000/µL  | 0/µL            |
| Glucose                     | 39 mg/dL   | 40–70 mg/dL     |
| Protein                     | 102 mg/dL  | 15–60 mg/dL     |

**TABLE 1: Laboratory findings of the patient.**

**FIGURE 1:** CT of the abdomen and pelvis showing mild hepatomegaly, mild splenomegaly, and possible splenic infarcts (A, yellow circle). CT of the head without contrast showing no acute intracranial process (B). TTE with a normal ejection fraction of 55%, no valvular vegetation, and BAV with mild stenosis (C).

CT: computed tomography; TTE: transthoracic echocardiogram; BAV: bicuspid aortic valve

The patient was empirically treated with IV ceftriaxone and vancomycin for possible sepsis. Urine culture grew *S. marcescens*. The patient continued to have fever, chills, and developed neck stiffness the following
day of the admission; hence, a lumbar puncture was performed to rule out meningitis. Cerebrospinal fluid (CSF) analysis laboratory findings are listed in Table 1. Doxycycline was added to cover any tick-borne illnesses due to recent history of hiking. Infectious disease was consulted. Blood and CSF cultures were negative for any growth. CSF meningitis polymerase chain reaction panel was negative. A wide range of bacterial, viral, and fungal serologies, including tick and hepatitis panels, were performed all of which were negative. On day six of hospitalization, a transesophageal echocardiogram was performed as the patient continued to have high-grade fevers with chills and left upper quadrant abdominal pain. It showed linear echo density measuring 1.9 cm on the aortic aspect of the aortic valve concerning for vegetation (Figure 2). The intervalvular fibrosa appeared mildly thickened, although not diagnostic for abscess. MRI of the brain showed multiple brain abscesses secondary to septic emboli from aortic valve endocarditis (Figures 3A, 3B). Ceftriaxone was discontinued and meropenem was added to vancomycin and doxycycline. Anticoagulation was not initiated for splenic infarcts due to multiple brain abscesses.

FIGURE 2: Transesophageal echocardiogram showing linear echo density measuring 1.9 cm on the aortic aspect of the aortic valve concerning for vegetation (yellow arrow).
Bone marrow biopsy showed hypercellular marrow with no increased blast population. Molecular testing was positive for BCR-ABL, consistent with the diagnosis of CML. MRI of the brain with/without contrast was repeated due to the worsening symptoms of occipital headache, new-onset blurring of vision, diplopia, nystagmus, vertigo, transient right facial droop, and left transient visual field defect. It showed acute new infarct in the right cerebellum, new abnormal flow within right vertebral artery suggestive of acute occlusion, demonstration of abnormal flow in the left vertebral artery suggestive of subacute or chronic occlusion, and multifocal lesions involving the cerebellum, bilateral occipital lobes, and parietal lobes consistent with multifocal abscesses with edema (Figures 4A-4C). The patient was then started on IV heparin for anticoagulation due to the risk of emboli propagation. At this time, vancomycin and doxycycline were discontinued and the patient was treated with meropenem and linezolid for endocarditis.

The patient had a repeat ultrasound of the abdomen that showed a large splenic abscess which prompted open splenectomy (Figure 5A). The decision was made to perform mechanical aortic valve replacement following the splenectomy for source control. Aortic valve vegetation was sent for microbiological analysis. Post-surgery, the patient developed confusion, worsening of the headache, and drowsiness. Repeat CT of the head without contrast revealed increased edema causing compression of the fourth ventricle resulting in acute hydrocephalus (Figure 5B), related to a large cerebellar infarct (Figure 5C). This was managed with hypertonic saline, acetazolamide, and the placement of an external ventricular drain. Approximately 10 days from admission, the patient was found to have progressively worsening thrombocytosis with platelets
counts ranging 109,1000–184,1000/µL (reference range: 140,000–400,000/µL). The patient’s thrombocytosis was thought to be secondary to splenectomy; however, underlying infections/sepsis and CML could also have contributed. Hematology recommended hydroxyurea and the dose was gradually increased to 1 g twice daily. The patient’s neurological status gradually improved and a repeat CT scan of the head showed progressively decreasing fourth ventricle size (Figure 5D). The tube was taken out on the 25th day of admission. Heparin infusion was discontinued following the external ventricular drain removal and the patient was transitioned to warfarin for a prosthetic aortic valve. Meanwhile, splenic abscess culture grew *Candida albicans*, which was treated with fluconazole.

**FIGURE 5**: Ultrasound of the abdomen: large splenic abscess (yellow arrow in A). CT of the head without contrast showing acute hydrocephalus (blue arrow in B), and a large cerebellar infarct (orange arrow in C). Repeat CT of the head showing improvement in hydrocephalous (green arrow in D).

CT: computed tomography

*S. marcescens* DNA was detected with the 16S rRNA gene primer set in the aortic vegetation after about three to four weeks of admission. The patient continued to have thrombocytosis, for which hydroxyurea dose was increased to 2 g daily and plateletpheresis was done to avoid thrombosis/bleeding complications. The patient was treated with a six-week course of meropenem for *Serratia* endocarditis with good response and was also initiated on treatment for CML prior to discharge.

**Discussion**

*Serratia* species are facultatively anaerobic gram-negative bacilli of the Enterobacteriaceae group. *Serratia* species are motile and can adhere to cells via fimbriae. The genus *Serratia* consists of at least 20 species, of which eight are known to cause infections in humans [1]. *S. marcescens* is the main human pathogen and produces a few different hemolysins that are toxic to different cell types [2]. *S. marcescens* and several other *Serratia* species encode an inducible, chromosomal AmpC beta-lactamase, although it is typically expressed at low levels. The low levels at which this enzyme is typically expressed, AmpC beta-lactamase mediates resistance to several beta-lactam antibiotics, such as penicillin and first-generation cephalosporins [3].

Endocarditis is most commonly caused by gram-positive bacteria, and among the gram-negative organisms, *Escherichia coli* is the most common pathogen followed by *Pseudomonas aeruginosa* and *Klebsiella*.
Serratia species has been occasionally recognized as the cause of healthcare-associated bacteremia due to the contamination of blood products, cleaning solutions, and inadequate sterile techniques with IV medications. However, a recent population-based study of Serratia species infections, including bacteremia in Canada, showed that 65% of infections were community-acquired; similar reports from Australia revealed that 47% of bacteremia episodes were community-acquired [7]. Although S. marcescens is the most common cause of endocarditis in the Serratia genus, cases of S. liquefaciens IE were reported in a patient with an intravascular central catheter (IVC)-related suppurative thrombophlebitis [8].

IE by S. marcescens was first described in the medical literature as a case series of 19 patients observed in the San Francisco Bay Area, 12 of whom were IVDU [9]. Endocarditis caused by S. marcescens has been seen most commonly in IVDU, and in one report it caused 14% of all addict-associated endocarditis cases [9]. Among these patients, most cases of right-sided endocarditis were cured by antibiotics alone while most cases of left-sided endocarditis treated medically alone did not survive. Most other cases of endocarditis caused by S. marcescens have occurred in patients with prosthetic heart valves. Only two cases of native valve endocarditis due to S. marcescens have been reported in the literature [10,11]. Both had right-sided involvement and indwelling IVC at the time of diagnosis and were successfully treated medically. An experimental endocarditis rabbit model using S. marcescens confirmed the significance of the presence of an indwelling catheter in the development of endocarditis [12].

In IVDU, injection of foreign antigens can precipitate antibody production that leads to immune complex deposition on valvular surfaces, which forms nidi for bacterial adhesion [13]. Studies have shown that IVDUs have "immunologic dysregulation" even when not HIV infected. It has been noted that HIV seropositive patients with CD4 cell counts of <350 cells/µL had an odds ratio (OR) of 2.31 for developing IE, whereas those with a CD4 cell count of <350 cells/µL had an OR of 8.31 [14]. Patients with abnormal immune functioning may not be unable to clear bacteria and are at risk of severe sepsis. The prognosis of endocarditis is also influenced by the immune status of the patient [15]. The evolution of vegetation size, its mobility and consistency, the extent of the disease, and the severity of valvular regurgitation have been related to late complications. With therapeutic options including modern antibiotic treatment and early surgical intervention, IE turned out to be a curable disease [16]. A case of ciprofloxacin-resistant S. marcescens in a non-Hodgkin lymphoma who was receiving ciprofloxacin for neutropenic prophylaxis has been reported but there are no case reports involving CML patients [17], as in our patient.

Serratia endocarditis is left-sided in IVDU [18]. Forty percent of S. marcescens endocarditis cases involve AV and septic embolization is common [19], which is consistent with our case. Because mortality rates are high with just medical therapy [19], a combination of medical and surgical management is recommended for left-sided endocarditis by Serratia. Most cases of right-sided endocarditis resolve with appropriate antibiotic administration without the need for further surgical management [20].

Conclusions

There are several unique features in our reported case. As mentioned, our patient had no commonly reported risk factors for Serratia endocarditis such as IVDU, cardiac devices, prosthetic heart valve, and indwelling catheters. He had left-sided endocarditis with involvement of the native aortic valve which was not initially detected on the TTE. Because mortality rates are high with just medical therapy, a combination of medical and surgical management is recommended for left-sided endocarditis; most cases of right-sided endocarditis resolve with medical management. Our patient needed surgical intervention due to progressive embolic phenomena despite the medical therapy and size of the vegetation (1.9 cm). Another unique feature is that the patient survived after a morbid hospital course and multiple surgical procedures. He had underlying CML which might have led to an immunocompromised state and subsequent superinfection with Serratia from the urinary source and its subsequent dissemination. To our knowledge, this is the first reported case in the literature of a patient with left-sided Serratia endocarditis and underlying CML.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the
submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Genus Serratia. (2019). Accessed: January 9, 2019: http://www.bacterio.net/serratia.html
2. Mahlen SD: Serratia infections: from military experiments to current practice. Clin Microbiol Rev. 2011, 24:755-91. 10.1128/CMR.00017-11
3. Hanson ND, Sanders CC: Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. Curr Pharm Des. 1999, 5:881-94.
4. Falcone M, Thuo G, Durante-Mangoni E, et al.: Risk factors and outcomes of endocarditis due to non-HACEK gram-negative bacilli: data from the prospective multicenter Italian endocarditis study cohort. Antimicrob Agents Chemother. 2018, 62:e0208-17. 10.1128/AAC.0208-17
5. Maskarinec SA, Thaden JT, Cyr DD, Ruffin F, Souli M, Fowler VG: The risk of cardiac device-related infection in bacteremic patients is species specific: results of a 12-year prospective cohort. Open Infect Dis. 2017, 4:sfx152. 10.1093/ofid/sfx152
6. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med. 1985, 13:818-29.
7. Morpeth S, Murdoch D, Cabell CH, et al.: Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med. 2007, 147:829-35. 10.7326/0003-4819-147-12-200712180-00002
8. Moossad SB: The world’s first case of Serratia liquefaciens intravascular catheter-related supplicative thrombophlebitis and native valve endocarditis. Clin Microbiol Infect. 2000, 6:559-60. 10.1046/j.1469-0691.2000.00164.x
9. Mills J, Drew D: Serratia marcescens endocarditis: a regional illness associated with intravenous drug abuse. Ann Intern Med. 1976, 84:29-35. 10.7326/0003-4819-84-1-29
10. Hyams KC, Mader JT, Pollard RB, Thomson PD, Reinarz JA: Serratia endocarditis in a pediatric burn patient. Cure with cefotaxime. JAMA. 1981, 246:983-4. 10.1001/jama.1981.03320090045029
11. Pearlman SA, Higgins S, Eppes S, Bhat AM, Klein JD: Infective endocarditis in the premature neonate. Clin Pediatr (Phila). 1998, 37:741-6. 10.1177/000992289803701205
12. Gutschik E, Müller S, Christensen N: Experimental endocarditis in rabbits. 3. Significance of the proteolytic capacity of the infecting strains of Streptococcus faecalis. Acta Pathol Microbiol Scand B. 1979, 87:553-62. 10.1111/j.1699-0463.1979.tb02450.x
13. Sullam PM, Drake TA, Sande MA: Pathogenesis of endocarditis. Am J Med. 1985, 78:110-5. 10.1016/0002-9343(85)90373-0
14. Werner AS, Cobbis CG, Kaye D, Hook EW: Studies on the bacteremia of bacterial endocarditis. JAMA. 1967, 202:199-203. 10.1001/jama.1967.03150106075013
15. Frontera JA, Gradon JD: Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin Infect Dis. 2000, 30:574-9. 10.1086/315664
16. Dokić M, Milanović M, Begović V, Ristić-Andelkov A, Tomanović B: [Infective endocarditis of a rare etiology (Serratia marcescens)]. Vojnosanit Pregl. 2004, 61:689-94. 10.2298/vsp0406689d
17. Körner RJ, Nicol A, Reeves DS, MacGowan AP, Hows J: Ciprofloxacin resistant Serratia marcescens endocarditis as a complication of non-Hodgkin’s lymphoma. J Infect. 1994, 29:73-6. 10.1016/s0163-4653(94)95141-1
18. Hadano Y, Kaniya T, Uenishi N: A fatal case of infective endocarditis caused by an unusual suspect: Serratia marcescens. Intern Med. 2012, 51:1425-8. 10.2169/internalmedicine.51.6648
19. Chua Loy H, Chua Loy P, Cheng HH, Hsueh PR: Aortic valve infective endocarditis caused by Serratia liquefaciens. J Infect. 2007, 54:e161-3. 10.1016/j.ijinf.2006.10.005
20. Akinosoglou K, Apostolakis E, Marangos M, Pasvoll G: Native valve right sided infective endocarditis. Eur J Intern Med. 2015, 24:510-9. 10.1016/j.ejim.2013.01.010